315 -5 (79) 2025 - Pak U.I., Narzikulov R.M. - COMPARATIVE ANALYSIS OF THE EFFICACY OF BIOLOGIC DRUGS IN SEVERE PSORIASIS

COMPARATIVE ANALYSIS OF THE EFFICACY OF BIOLOGIC DRUGS IN SEVERE PSORIASIS

Pak U.I. - Dermatovenerologist of Samarkand regional branch of the Republican Specialized Dermatovenerological and Cosmetological Scientific and Practical Medical Center

Narzikulov R.M. - Samarkand State Medical University

Resume

Severe psoriasis requires systemic therapy, and biologic agents targeting key pro-inflammatory cytokines (TNF-α, IL-17, IL-23) have demonstrated high clinical efficacy and a favorable safety profile. This comparative study evaluated the efficacy of three biologic agents, adalimumab, secukinumab, and guselkumab, in 90 patients with severe plaque psoriasis. The degree of repigmentation was monitored for 16 weeks using the PASI scale (75, 90 and 100), as well as the dynamics of quality of life using the DLQI. The data showed that secukinumab provided the most rapid early symptom reduction, while guselkumab demonstrated the best rates of sustained remission and complete skin repigmentation. The side effect profile in all groups was comparable and did not require withdrawal of therapy. The results underscore the need for a personalized approach to the selection of a biologic agent, taking into account disease severity, clinical response rate and individual tolerability

Keywords: psoriasis, biologic therapy, IL-23, IL-17, adalimumab, guselkumab, secukinumab, PASI, clinical efficacy

First page

1583

Last page

1587

For citation:Pak U.I., Narzikulov R.M. - COMPARATIVE ANALYSIS OF THE EFFICACY OF BIOLOGIC DRUGS IN SEVERE PSORIASIS//New Day in Medicine 5(79)2025 1583-1587 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

  1. Reich K. et al. A review of biologics targeting IL-23 in psoriasis. J Eur Acad Dermatol Venereol. 2021.
  2. Langley R.G. et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014.
  3. Gordon K.B. et al. Efficacy of guselkumab in patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2020.
  4. Menter A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2019.
  5. Utayev A. J., Tolibov M. M., Axmedova M. M. MANAGEMENT APPROACHES FOR CHRONIC URETHROGENIC PROSTATITIS //Modern Scientific Research International Scientific Journal. – 2024. – Т. 2. – №. 1. – С. 151-156.

    file

    download